Rocket Lab Is Buying Iridium, and Guess What? Iridium Just Beat Earnings!

Iridium reported Q3 2026 profit of $0.98 per share versus analysts’ $0.34 estimate and revenue of $245.7 million versus $236.3 million, with Aireon contributing to year-over-year revenue growth of 8%. Rocket Lab’s planned $8 billion acquisition of Iridium, approved by Iridium shareholders, is expected to close mid-2027; the article estimates the combined company could generate about $300 million of positive free cash flow next year. However, at Rocket Lab’s cited $45 billion market capitalization, that implies a roughly 150x forward price-to-free-cash-flow ratio, leaving the stock’s valuation demanding despite the deal’s potential benefits.

Analysis

The key underwriting question is whether Iridium’s reported profit strength converts into durable, post-close cash flow—not whether one quarter beat estimates. The article attributes much of the earnings upside to bringing Aireon in-house; verify how much is recurring operating income versus acquisition-related or other non-cash/accounting effects, and reconcile reported earnings with cash generation. The apparent 2027 cash-flow cushion for Rocket Lab is conditional: deal financing, incremental interest, share issuance, capex, integration costs, and the actual closing date could materially change the pro forma result. Shareholder approval is not closing certainty.

Strategically, Aireon could give Rocket Lab a differentiated data asset and cross-sell path into aviation monitoring and adjacent connectivity services. But “only” describes a claimed system position, not guaranteed pricing power; customers may retain terrestrial alternatives, and converting an established Iridium service into growth for Rocket Lab’s newer markets is execution risk. Iridium’s relatively steady cash generation may reduce Rocket Lab’s funding pressure, but does not by itself validate the much larger valuation attached to Rocket Lab’s growth options. At the article’s cited valuation and FCF estimate, the implied multiple leaves little room for forecast slippage.

Near term, the market may focus on deal terms and comparable, cash-based Iridium results rather than the headline EPS beat. Over 1–3 months, review merger filings and pro forma financing; over 6–18 months, monitor close timing, churn/renewals, service revenue, and consolidated FCF. The thesis improves if recurring Iridium cash flow is confirmed and Rocket Lab funds the transaction without material dilution or leverage strain; it weakens on delay, adverse financing, or FCF below plan.

Key Decisions for Investors

• Do not chase RKLB on the Iridium beat alone. For existing overweight exposure, consider trimming or using a defined-risk put spread rather than an outright short; the deal adds real strategic value, but the cited valuation makes execution misses asymmetric.
• Treat the claimed 2027 FCF uplift as a watch item, not a base-case underwriting input, until filings disclose consideration, funding mix, pro forma interest expense, and whether Iridium’s earnings and FCF figures are comparable and recurring.
• No IRDM/RKLB merger-arbitrage pair is justified from the supplied information: consideration terms, exchange ratio, and closing conditions are absent. Reassess once those are disclosed and the spread can be measured.
• Falsifiers: a materially dilutive or debt-heavy funding plan, closing slippage beyond the expected mid-2027 window, or post-close Iridium recurring FCF below forecast. Conversely, verified recurring cash generation and limited incremental financing costs would support holding RKLB exposure despite the valuation risk.